{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T11:13:08Z","timestamp":1781521988414,"version":"3.54.1"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Sports Act. Living"],"abstract":"<jats:p>The establishment of an anti-doping rule violation extends beyond the mere detection of a prohibited substance. Current interpretation criteria rely primarily on urinary concentration estimates, which may be misleading due to high interindividual variability or pharmacokinetics characteristics of doping agents. This study investigates the potential of capillary blood collected through volumetric absorptive microsampling (VAMS) as a complementary matrix to urine for supporting results management in doping control. Comparative concentration-time profiling in urine and capillary blood was performed using isometheptene, a stimulant subject to minimum reporting limits (MRLs), and the carbonic anhydrase II inhibitors dorzolamide and brinzolamide as model compounds. For isometheptene, capillary blood detection closely mirrored urinary findings at early time points but exhibited a markedly shorter detection window, supporting improved discrimination between in-competition and out-of-competition administration in cases where urinary concentrations alone may lead to ambiguous interpretation. In contrast, for the long-lasting diuretics brinzolamide and dorzolamide, urinary concentrations showed limited interpretative value, whereas capillary blood analysis provided more consistent detectability, reflecting their strong affinity for red blood cells. However, capillary blood concentrations did not allow unequivocal discrimination between permitted ophthalmic use and prohibited administration routes. Overall, these findings demonstrate that capillary blood analysis can enhance interpretative context of anti-doping result management, particularly for substances with complex pharmacokinetics, and provide a scientific basis for the future establishment of blood-based reporting criteria.<\/jats:p>","DOI":"10.3389\/fspor.2026.1755735","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T23:10:09Z","timestamp":1771456209000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Stressing the limits of capillary blood in anti-doping analysis: perspectives on alkylamine-like stimulants and carbonic anhydrase II inhibitors in result management"],"prefix":"10.3389","volume":"8","author":[{"given":"Isabelle Karine","family":"da Costa Nunes","sequence":"first","affiliation":[{"name":"Brazilian Doping Control Laboratory (LBCD), Institute of Chemistry, Federal University of Rio de Janeiro (UFRJ)","place":["Rio de Janeiro, RJ, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Vaz Carneiro","sequence":"additional","affiliation":[{"name":"Brazilian Doping Control Laboratory (LBCD), Institute of Chemistry, Federal University of Rio de Janeiro (UFRJ)","place":["Rio de Janeiro, RJ, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Alves Gomes de Oliveira","sequence":"additional","affiliation":[{"name":"Brazilian Doping Control Laboratory (LBCD), Institute of Chemistry, Federal University of Rio de Janeiro (UFRJ)","place":["Rio de Janeiro, RJ, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Carolina","family":"Dudenhoeffer Carneiro","sequence":"additional","affiliation":[{"name":"Brazilian Doping Control Laboratory (LBCD), Institute of Chemistry, Federal University of Rio de Janeiro (UFRJ)","place":["Rio de Janeiro, RJ, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"de Souza Anselmo","sequence":"additional","affiliation":[{"name":"Brazilian Doping Control Laboratory (LBCD), Institute of Chemistry, Federal University of Rio de Janeiro (UFRJ)","place":["Rio de Janeiro, RJ, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Farias Trajano","sequence":"additional","affiliation":[{"name":"Brazilian Doping Control Laboratory (LBCD), Institute of Chemistry, Federal University of Rio de Janeiro (UFRJ)","place":["Rio de Janeiro, RJ, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Costa Padilha","sequence":"additional","affiliation":[{"name":"Brazilian Doping Control Laboratory (LBCD), Institute of Chemistry, Federal University of Rio de Janeiro (UFRJ)","place":["Rio de Janeiro, RJ, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrique Marcelo","family":"Gualberto Pereira","sequence":"additional","affiliation":[{"name":"Brazilian Doping Control Laboratory (LBCD), Institute of Chemistry, Federal University of Rio de Janeiro (UFRJ)","place":["Rio de Janeiro, RJ, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"B1","year":"2021"},{"key":"B2","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s40318-020-00176-6","article-title":"A level playing field in anti-doping disputes? The need to scrutinize procedural fairness at first instance hearings","volume":"21","author":"Star","year":"2021","journal-title":"ISLJ"},{"key":"B3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.16469\/J.css.2024KX034","article-title":"Determining factors on ineligibility period reduction or elimination for contaminant ingestion of anti-doping rule violations\u2014an empirical study based on the arbitral awards of the court of arbitration for sport from 2014 to 2024","volume":"44","author":"Xiao","year":"2024","journal-title":"China Sport Sci"},{"key":"B4","year":"2025"},{"key":"B5","year":"2022"},{"key":"B6","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/dta.2790","article-title":"Do dried blood spots (DBS) have the potential to support result management processes in routine sports drug testing?","volume":"12","author":"Thevis","year":"2020","journal-title":"Drug Testing Anal"},{"key":"B7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/dta.3156","article-title":"Case reports: unintended anti-doping rule violation after dorzolamide use several months prior to a doping control","volume":"13","author":"Pokrywka","year":"2021","journal-title":"Drug Testing Anal"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1124\/dmd.111.040055","article-title":"Ocular pharmacokinetics of dorzolamide and brinzolamide after single and multiple topical dosing","volume":"39","author":"Kadam","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"B9","doi-asserted-by":"publisher","first-page":"S119","DOI":"10.1016\/S0039-6257(99)00108-3","article-title":"Preclinical overview of brinzolamide","volume":"44","author":"DeSantis","year":"2000","journal-title":"Surv Ophthalmol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"197","DOI":"10.2165\/00003088-200241030-00004","article-title":"Clinical pharmacokinetics of dorzolamide","volume":"41","author":"Martens-Lobenhoffer","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1002\/dta.3011","article-title":"Do dried blood spots have the potential to support result management processes in routine sports drug testing?\u2014part 2: proactive sampling for follow-up investigations concerning atypical or adverse analytical findings","volume":"13","author":"Thevis","year":"2021","journal-title":"Drug Testing Anal"},{"key":"B12","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1002\/dta.3463","article-title":"Do dried blood spots have the potential to support result management processes in routine sports drug testing?\u2014part 3: lC\u2013MS\/MS-based peptide analysis for dried blood spot sampling time point estimation","volume":"16","author":"Brockbals","year":"2024","journal-title":"Drug Testing Anal"},{"key":"B13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.4155\/bio-2021-0019","article-title":"Dried blood spots in doping analysis","volume":"13","author":"Yuan","year":"2021","journal-title":"Bioanal"},{"key":"B14","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1039\/C5AY01514F","article-title":"Dried blood spots (DBS) in doping controls: a complementary matrix for improved in-and out-of-competition sports drug testing strategies","volume":"7","author":"Tretzel","year":"2015","journal-title":"Anal Methods"},{"key":"B15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/dta.3338","article-title":"Analysis of dried blood spots is a feasible alternative for detecting ephedrine in doping control","volume":"14","author":"Solheim","year":"2022","journal-title":"Drug Test Anal"},{"key":"B16","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/dta.70008","article-title":"Improvement of EPO transgene detection from polymeric dried blood spots for antidoping application","volume":"18","author":"Marchand","year":"2026","journal-title":"Drug Test Anal"},{"key":"B17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/FTD.0000000000001083","article-title":"Applications of volumetric absorptive microsampling technique: a systematic critical review","volume":"45","author":"Dodeja","year":"2023","journal-title":"Ther Drug Monit"},{"key":"B18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/17576180.2025.2546782","article-title":"How microsampling is impacting pharmacokinetic and toxicokinetic studies: volumetric absorptive microsampling (VAMS)","volume":"17","author":"Protti","year":"2025","journal-title":"Bioanal"},{"key":"B19","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1002\/dta.3603","article-title":"Application of micro capillary blood sampling in an anti-doping setting","volume":"16","author":"Lewis","year":"2024","journal-title":"Drug Test Anal"},{"key":"B20","doi-asserted-by":"publisher","first-page":"31845","DOI":"10.1021\/acsomega.2c01417","article-title":"UHPLC\u2013HRMS method for the simultaneous screening of 235 drugs in capillary blood for doping control purpose: comparative evaluation of volumetric and non-volumetric dried blood spotting devices","volume":"7","author":"Mazzarino","year":"2022","journal-title":"ACS Omega"},{"key":"B21","unstructured":"Heiland\n              CE\n            \n          \n          Stockholm\n          Karolinska Institutet\n          Advancements in detection of performance enhancing drugs in dried blood spots\u2013focusing on erythropoietin\n          \n          2024"},{"key":"B22","doi-asserted-by":"publisher","first-page":"117048","DOI":"10.1016\/j.jpba.2025.117048","article-title":"Comparability of different analytical workflows for steroids esters detection in doping control field","volume":"265","author":"Mazzarino","year":"2025","journal-title":"J Pharm Biomed Anal"},{"key":"B23","year":"2026"},{"key":"B24","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/dta.3596","article-title":"Dried blood spots for erythropoietin analysis: detection of micro-doses, EPO c.577del variant and comparison with in-competition matching urine samples","volume":"16","author":"Heiland","year":"2023","journal-title":"Drug Testing Anal"},{"key":"B25","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/dta.2975","article-title":"On the road of dried blood spot sampling for antidoping tests: detection of GHRP-2 abuse","volume":"13","author":"Reverter-Branchat","year":"2021","journal-title":"Drug Test Anal"},{"key":"B26","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1002\/dta.342C","article-title":"Dried blood spots (DBS) for doping control analysis","volume":"3","author":"Thomas","year":"2011","journal-title":"Drug Test Anal"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s00216-011-5655-2","article-title":"Sensitive determination of prohibited drugs in dried blood spots (DBS) for doping controls by means of a benchtop quadrupole\/orbitrap mass spectrometer","volume":"403","author":"Thomas","year":"2012","journal-title":"Anal Bioanal Chem"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1002\/dta.3135","article-title":"No pain, just gain: painless, easy, and fast dried blood spot collection from fingertip and upper arm in doping control","volume":"13","author":"Solheim","year":"2021","journal-title":"Drug Test Anal"},{"key":"B29","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.1007\/s00216-020-02634-4","article-title":"Fully automated dried blood spot sample preparation enables the detection of lower molecular mass peptide and non-peptide doping agents by means of LC-HRMS","volume":"412","author":"Lange","year":"2020","journal-title":"Anal Bioanal Chem"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e5633","DOI":"10.1002\/bmc.5633","article-title":"Dried blood spots for doping controls\u2014development of a comprehensive initial testing procedure with fully automated sample preparation","volume":"37","author":"Garzinsky","year":"2023","journal-title":"Biomed Chromatogr"},{"key":"B31","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1055\/s-0036-1582317","article-title":"Analyses of meldonium (mildronate) from blood, dried blood spots (DBS), and urine suggest drug incorporation into erythrocytes","volume":"37","author":"Tretzel","year":"2016","journal-title":"Int J Sports Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jpba.2014.03.013","article-title":"Use of dried blood spots in doping control analysis of anabolic steroid esters","volume":"96","author":"Tretzel","year":"2014","journal-title":"J Pharm Biomed Anal"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1002\/dta.3889","article-title":"Analysis of testosterone esters in serum and DBS samples\u2014results from an interlaboratory study","volume":"17","author":"Langer","year":"2025","journal-title":"Drug Test Anal"},{"key":"B34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/dta.3959","article-title":"Evaluating the testosterone-to-luteinizing hormone ratio in male anti-doping Serum samples: results from a transdermal testosterone administration trial and field collected samples","volume":"18","author":"Goodrum","year":"2026","journal-title":"Drug Testing Anal"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1002\/dta.3932","article-title":"Detection of a single microdose of testosterone and recombinant EPO in healthy volunteers","volume":"17","author":"Heiland","year":"2025","journal-title":"Drug Testing Anal"},{"key":"B36","doi-asserted-by":"publisher","first-page":"114280","DOI":"10.1016\/j.jpba.2021.114280","article-title":"Steroid profiling by UHPLC-MS\/MS in dried blood spots collected from healthy women with and without testosterone gel administration","volume":"204","author":"Salamin","year":"2021","journal-title":"J Pharm Biomed Anal"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1002\/dta.3059","article-title":"EPO Transgene detection in dried blood spots for antidoping application","volume":"13","author":"Marchand","year":"2021","journal-title":"Drug Test Anal"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1002\/dta.3341","article-title":"Detection of erythropoiesis stimulating agent luspatercept after administration to healthy volunteers for antidoping purposes","volume":"14","author":"Marchand","year":"2022","journal-title":"Drug Test Anal"},{"key":"B39","year":"2023"},{"key":"B40","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/bmc.1367","article-title":"Dried blood spot sampling in combination with LC-MS\/MS for quantitative analysis of small molecules","volume":"24","author":"Li","year":"2010","journal-title":"Biomed Chromatogr"},{"key":"B41","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ecl.2009.10.011","article-title":"Stimulants and doping in sport","volume":"39","author":"Thevis","year":"2010","journal-title":"Endocrinol Metab Clin"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.3109\/10826084.2014.907653","article-title":"Stimulant doping agents used in Brazil: prevalence, detectability, analytical implications, and challenges","volume":"49","author":"Pereira","year":"2014","journal-title":"Subst Use Misuse"},{"key":"B43","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1002\/dta.3799","article-title":"Evaluation of Minimum reporting limits to determine in-competition use of stimulants","volume":"17","author":"Nair","year":"2025","journal-title":"Drug Testing Anal"},{"key":"B44","year":"2024"},{"key":"B45","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1136\/bjsports-2020-103512","article-title":"A novel approach to improve detection of glucocorticoid doping in sport with new guidance for physicians prescribing for athletes","volume":"55","author":"Ventura","year":"2021","journal-title":"Br J Sports Med"},{"key":"B46","year":"2025"},{"key":"B47","doi-asserted-by":"publisher","first-page":"100236","DOI":"10.1016\/j.jcoa.2025.100236","article-title":"Metabolite patterns of the carbonic anhydrase inhibitors brinzolamide and dorzolamide: potential markers for the route of application","volume":"8","author":"Jin","year":"2025","journal-title":"J Chromatogr Open"},{"key":"B48","doi-asserted-by":"publisher","first-page":"305","DOI":"10.2174\/1874364101711010305","article-title":"A single drop in the eye\u2014effects on the whole body?","volume":"11","author":"Vaajanen","year":"2017","journal-title":"Open Ophthalmol J"},{"key":"B49","first-page":"269","article-title":"Lack of increased diuresis after topical administration of the carbonic anhydrase inhibitor dorzolamide","author":"Mazzarino","year":"2001"},{"key":"B50","first-page":"127","article-title":"Carbonic anhydrase inhibitors: an evaluation of the excretion profile of dorzolamide after different administration routes and doses","author":"Mazzarino","year":"2018"},{"key":"B51","first-page":"82","article-title":"Detection of dorzolamide in athlete urine following ophthalmic application","author":"Grucza","year":"2018"},{"key":"B52","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0378-4347(96)00279-4","article-title":"Detection of diuretic agents in doping control","volume":"687","author":"Ventura","year":"1996","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1476-5381.2010.00789.x","article-title":"The abuse of diuretics as performance-enhancing drugs and masking agents in sport doping: pharmacology, toxicology and analysis","volume":"161","author":"Cadwallader","year":"2010","journal-title":"Br J Pharmacol"}],"container-title":["Frontiers in Sports and Active Living"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fspor.2026.1755735\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T23:10:11Z","timestamp":1771456211000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fspor.2026.1755735\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":53,"alternative-id":["10.3389\/fspor.2026.1755735"],"URL":"https:\/\/doi.org\/10.3389\/fspor.2026.1755735","relation":{},"ISSN":["2624-9367"],"issn-type":[{"value":"2624-9367","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"article-number":"1755735"}}